Biotricity, Inc.

Equities

BTCY

US09074H2031

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
1.28 ^USD	-1.54%		-5.19%	+11.30%

Apr. 26	Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro	CI
Apr. 19	Top Premarket Decliners	MT

BIOTRICITY INC. : Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant (form 8-K)

January 27, 2023 at 05:08 pm EST

Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On January 23rd. 2023, Biotricity Inc. (the "Company") received $2,000,000 in cash proceeds from an existing investor. The Company and the investor are in the process of finalizing the final documentation but Company expects to issue the investor a promissory note with matures in 18-months and has an accrued interest rate of 10%. The promissory note will contain other customary provisions.

Latest news about Biotricity, Inc.

Biotricity Inc. Announces High Demand for Its Latest Device, Biotres Pro	Apr. 26	CI
Top Premarket Decliners	Apr. 19	MT
Biotricity, Inc. announced that it has received $2 million in funding	Apr. 08	CI
Biotricity Announces Strategic Partnership for Cardiac Screenings in Patients with Co-Morbidities	Apr. 02	CI
Biotricity, Inc. announced a financing transaction	Mar. 24	CI
Biotricity Unveils That Improved Margins Resulted from Latest Advancements to Its Proprietary Cardiac Ai Cloud Platform and Announces Plans for Continued Expansion of Its Cardiac AI Cloud	Mar. 12	CI
Biotricity, Inc. Solidifies It's Presence in the Healthcare Landscape	Mar. 05	CI
Transcript : Biotricity, Inc., Q3 2024 Earnings Call, Feb 21, 2024	Feb. 21
Biotricity, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 20	CI
Biotricity Inc. Expands Development of its Cardiac AI Cloud Platform with Data Ecosystem of over 360 Billion Heartbeats	Jan. 23	CI
HC Wainwright Downgrades Biotricity to Neutral From Buy	Nov. 20	MT
Transcript : Biotricity, Inc., Q2 2024 Earnings Call, Nov 14, 2023	Nov. 14
Biotricity, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 14	CI
Biotricity Releases Another Groundbreaking Product: Biotres Pro	23-10-31	CI
Biotricity Files Patent for Wearable Heart Monitoring Device Bioheart	23-10-10	MT
Biotricity Continues to Expand Patent Portfolio with Latest Patent Filing for Bioheart Device	23-10-10	CI
Biotricity, Inc. Announces Patent Filing for Cutting-Edge Biotres Device	23-10-03	CI
Transcript : Biotricity, Inc., Q1 2024 Earnings Call, Aug 15, 2023	23-08-15
Biotricity, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-14	CI
Biotricity Expands Amazon, Google Partnership for Remote Cardiac Monitoring Technology	23-07-25	MT
Biotricity Inc. Expands Its Proprietary AI Model and Deepens Relationship with Amazon Aws and Google's Tensor Flow for Remote Cardiac Care Applications	23-07-25	CI
HC Wainwright Adjusts Biotricity Price Target to $4 From $12 After 1-for-6 Reverse Stock Split, Maintains Buy Rating	23-07-07	MT
Biotricity, Inc. Provides Earnings Guidance for the First Fiscal Quarter Ended June 30, 2023	23-07-06	CI
HC Wainwright Adjusts Biotricity Price Target to $4 From $12, Maintains Buy Rating	23-07-05	MT
Monday's Top Decliners	23-07-03	MT

Chart Biotricity, Inc.

Duration

Period

More charts

Company Profile

Biotricity Inc. is a medical technology company focused on biometric data monitoring and diagnostic solutions. The Company developed its Bioflux technology, comprised of a monitoring device and software components. The Bioflux device is comprised of a wet electrode worn on a belt clip around the waist. The Bioflux ECG reporting software enables doctors and labs to view a patientâs electrocardiogram (ECG) data for monitoring and diagnostic purposes. Its Bioflux platform has a built-in cellular chipset and a real-time embedded operating system, which allows for its technology to be utilized as an Internet of Things (IoT) platform. It has developed several technologies, including Biotres, Bioheart, and Biocare. Biotres is an ECG Holter solution that addresses the limitations of existing solutions in the Holter market. Bioheart is a personal cardiac monitoring solution for consumers. Biocare is a cardiac disease management platform for chronic care management and remote patient monitoring.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-06-19 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

1.28

Average target price

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Medical Monitoring Systems

	1st Jan change	Capi.
BIOTRICITY, INC.	+11.30%	12.12M
IRHYTHM TECHNOLOGIES, INC.	+4.55%	3.48B
EKF DIAGNOSTICS HOLDINGS PLC	-12.80%	156M
MEDIANA CO.,LTD	-15.69%	81.85M
NEUROTECH INTERNATIONAL LIMITED	+30.43%	59.71M

Medical Monitoring Systems